Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | HRX-0233 + RMC-6236 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
HRX-0233 | HRX0233|HRX 0233 | HRX-0233 is a MAP2K4 inhibitor, which potentially synergizes with MAPK or KRAS inhibitors to decrease tumor growth (PMID: 38377196). | ||
RMC-6236 | RMC 6236|RMC6236 | RAS Inhibitor (Pan) 11 | RMC-6236 forms a binary complex with CypA, which prevents GTP-bound RAS from interacting with downstream effectors, potentially leading to anti-tumor activity (Cancer Res 2022;82(12_Suppl): Abstract nr 3597, PMID: 38593348). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|